Rapport Therapeutics Inc. Insider Trading
RAPP
7 insiders bought $22M of their own stock in 8 days.
Open-market purchases by executives and directors between Oct 21 and Oct 28. Buying is rarer than selling and says more, but it is one input, not a verdict.
Get an email when RAPP's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Oct 28 | James Healy Director | Bought 4 parts | 969,480 | $21.00 average | $20.4M | 51% | Form 4 |
| Oct 23 | Ramiro Sanchez Director | Bought | 3,600 | $27.35 | 98K | New | Form 4 |
| Oct 22 | Paul M Silva Director | Bought | 3,680 | $27.08 | 100K | New | Form 4 |
| Oct 22 | Wendy B. Young Director | Bought | 3,789 | $26.39 | 100K | 40% | Form 4 |
| Oct 22 | Steven M Paul Director | Bought | 35,714 | $27.28 | 974K | 6.9% | Form 4 |
| Oct 22 | John Maraganore Director | Bought 2 parts | 9,411 | $26.45 average | 249K | New | Form 4 |
| Oct 21 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan | 2,210 | $29.16 | 64K | 0.4% | Form 4 |
| Oct 21 | Troy A. Ignelzi Chief Financial Officer | Bought | 5,500 | $26.10 | 144K | 55% | Form 4 |
| Oct 6 – 7 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan 2 parts | 4,522 | $31.68 average | 143K | 0.8% | Form 4 |
| Sep 30 | Cheryl Gault Chief Operating Officer | Sold10b5-1 plan 2 parts | 10,000 | $33.19 average | 332K | 6.7% | Form 4 |
| Sep 23 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan 3 parts | 2,210 | $39.17 average | 87K | 0.4% | Form 4 |
| Sep 8 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan 2 parts | 8,210 | $45.62 average | 375K | 1.4% | Form 4 |
| Aug 25 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan | 18,921 | $49.57 | 938K | 3.2% | Form 4 |
| Aug 24 – 25 | Krishnaswamy Yeleswaram Chief Development Officer | Sold10b5-1 plan 3 parts | 50,160 | $50.47 average | $2.53M | 20% | Form 4 |
| Aug 19 | Krishnaswamy Yeleswaram Chief Development Officer | Sold10b5-1 plan | 404 | $49.90 | 20K | 0.2% | Form 4 |
| Aug 10 – 11 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan 5 parts | 51,499 | $47.24 average | $2.43M | 8.0% | Form 4 |
| Jul 27 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan 2 parts | 2,210 | $42.11 average | 93K | 0.3% | Form 4 |
| Jul 14 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan 2 parts | 8,210 | $40.00 average | 328K | 1.3% | Form 4 |
| Jun 30 | Cheryl Gault Chief Operating Officer | Sold10b5-1 plan 4 parts | 10,000 | $41.58 average | 416K | 6.3% | Form 4 |
| Jun 29 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan 2 parts | 8,220 | $39.83 average | 327K | 1.2% | Form 4 |
| May 26 | Third Rock Ventures V, L.p. Large holder | Sold10b5-1 plan | 18,572 | $40.05 | 744K | 0.3% | Form 4 |
| May 11 | Third Rock Ventures V, L.p. Large holder | Sold10b5-1 plan | 133,618 | $40.24 | $5.38M | 1.8% | Form 4 |
| May 7 – 8 | Third Rock Ventures VI, L.p. Large holder | Sold10b5-1 plan 2 parts | 276,513 | $40.12 average | $11.1M | 3.6% | Form 4 |
| Apr 17 | Third Rock Ventures VI, L.p. Large holder | Sold10b5-1 plan | 426,005 | $40.32 | $17.2M | 5.3% | Form 4 |
| Apr 17 | Krishnaswamy Yeleswaram Chief Development Officer | Sold10b5-1 plan | 20,225 | $39.99 | 809K | 7.6% | Form 4 |
| Apr 10 – 14 | Krishnaswamy Yeleswaram Chief Development Officer | Sold10b5-1 plan 3 parts | 19,865 | $35.03 average | 696K | 6.9% | Form 4 |
| Apr 8 | Krishnaswamy Yeleswaram Chief Development Officer | Sold10b5-1 plan | 360 | $34.90 | 13K | 0.1% | Form 4 |
| Mar 30 | Cheryl Gault Chief Operating Officer | Sold10b5-1 plan 2 parts | 10,000 | $28.18 average | 282K | 5.9% | Form 4 |
| Mar 25 | Krishnaswamy Yeleswaram Chief Development Officer | Sold10b5-1 plan | 10,115 | $29.99 | 303K | 3.4% | Form 4 |
| Mar 5 | Cheryl Gault Chief Operating Officer | SoldNo plan | 2,014 | $28.93 | 58K | 1.2% | Form 4 |
| Feb 18 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan 4 parts | 10,916 | $29.35 average | 320K | 1.6% | Form 4 |
| Feb 17 | David Bredt Chief Scientific Officer | Sold10b5-1 plan 3 parts | 8,500 | $29.02 average | 247K | 2.1% | Form 4 |
| Jan 20 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan 2 parts | 10,916 | $26.12 average | 285K | 1.6% | Form 4 |
| Jan 15 | David Bredt Chief Scientific Officer | Sold10b5-1 plan 2 parts | 8,500 | $26.84 average | 228K | 2.1% | Form 4 |
| Dec 31, 2025 | David Bredt Chief Scientific Officer | SoldNo plan | 6,567 | $30.05 | 197K | 1.6% | Form 4 |
| Dec 31, 2025 | Krishnaswamy Yeleswaram Chief Development Officer | SoldNo plan | 2,840 | $30.05 | 85K | 0.9% | Form 4 |
| Dec 17, 2025 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan 6 parts | 10,916 | $29.64 average | 324K | 1.6% | Form 4 |
| Dec 15, 2025 | David Bredt Chief Scientific Officer | Sold10b5-1 plan 2 parts | 8,500 | $30.02 average | 255K | 2.1% | Form 4 |
| Nov 26, 2025 | Cheryl Gault Chief Operating Officer | Sold10b5-1 plan | 5,000 | $30.10 | 151K | 2.8% | Form 4 |
| Nov 17, 2025 | Abraham Ceesay Chief Executive Officer | Sold10b5-1 plan 4 parts | 10,916 | $25.20 average | 275K | 1.6% | Form 4 |
- Oct 28James HealyDirector · bought 969,480 at avg $21.00$20.4M51% of stake
- Oct 23Ramiro SanchezDirector · bought 3,600 at $27.3598KNew position
- Oct 22Paul M SilvaDirector · bought 3,680 at $27.08100KNew position
- Oct 22Wendy B. YoungDirector · bought 3,789 at $26.39100K40% of stake
- Oct 22Steven M PaulDirector · bought 35,714 at $27.28974K6.9% of stake
- Oct 22John MaraganoreDirector · bought 9,411 at avg $26.45249KNew position
- Oct 2110b5-1 planAbraham CeesayChief Executive Officer · sold 2,210 at $29.1664K0.4% of stake
- Oct 21Troy A. IgnelziChief Financial Officer · bought 5,500 at $26.10144K55% of stake
- Oct 6 – 710b5-1 planAbraham CeesayChief Executive Officer · sold 4,522 at avg $31.68143K0.8% of stake
- Sep 3010b5-1 planCheryl GaultChief Operating Officer · sold 10,000 at avg $33.19332K6.7% of stake
- Sep 2310b5-1 planAbraham CeesayChief Executive Officer · sold 2,210 at avg $39.1787K0.4% of stake
- Sep 810b5-1 planAbraham CeesayChief Executive Officer · sold 8,210 at avg $45.62375K1.4% of stake
- Aug 2510b5-1 planAbraham CeesayChief Executive Officer · sold 18,921 at $49.57938K3.2% of stake
- Aug 24 – 2510b5-1 planKrishnaswamy YeleswaramChief Development Officer · sold 50,160 at avg $50.47$2.53M20% of stake
- Aug 1910b5-1 planKrishnaswamy YeleswaramChief Development Officer · sold 404 at $49.9020K0.2% of stake
- Aug 10 – 1110b5-1 planAbraham CeesayChief Executive Officer · sold 51,499 at avg $47.24$2.43M8.0% of stake
- Jul 2710b5-1 planAbraham CeesayChief Executive Officer · sold 2,210 at avg $42.1193K0.3% of stake
- Jul 1410b5-1 planAbraham CeesayChief Executive Officer · sold 8,210 at avg $40.00328K1.3% of stake
- Jun 3010b5-1 planCheryl GaultChief Operating Officer · sold 10,000 at avg $41.58416K6.3% of stake
- Jun 2910b5-1 planAbraham CeesayChief Executive Officer · sold 8,220 at avg $39.83327K1.2% of stake
- May 2610b5-1 planThird Rock Ventures V, L.p.Large holder · sold 18,572 at $40.05744K0.3% of stake
- May 1110b5-1 planThird Rock Ventures V, L.p.Large holder · sold 133,618 at $40.24$5.38M1.8% of stake
- May 7 – 810b5-1 planThird Rock Ventures VI, L.p.Large holder · sold 276,513 at avg $40.12$11.1M3.6% of stake
- Apr 1710b5-1 planThird Rock Ventures VI, L.p.Large holder · sold 426,005 at $40.32$17.2M5.3% of stake
- Apr 1710b5-1 planKrishnaswamy YeleswaramChief Development Officer · sold 20,225 at $39.99809K7.6% of stake
- Apr 10 – 1410b5-1 planKrishnaswamy YeleswaramChief Development Officer · sold 19,865 at avg $35.03696K6.9% of stake
- Apr 810b5-1 planKrishnaswamy YeleswaramChief Development Officer · sold 360 at $34.9013K0.1% of stake
- Mar 3010b5-1 planCheryl GaultChief Operating Officer · sold 10,000 at avg $28.18282K5.9% of stake
- Mar 2510b5-1 planKrishnaswamy YeleswaramChief Development Officer · sold 10,115 at $29.99303K3.4% of stake
- Mar 5No planCheryl GaultChief Operating Officer · sold 2,014 at $28.9358K1.2% of stake
- Feb 1810b5-1 planAbraham CeesayChief Executive Officer · sold 10,916 at avg $29.35320K1.6% of stake
- Feb 1710b5-1 planDavid BredtChief Scientific Officer · sold 8,500 at avg $29.02247K2.1% of stake
- Jan 2010b5-1 planAbraham CeesayChief Executive Officer · sold 10,916 at avg $26.12285K1.6% of stake
- Jan 1510b5-1 planDavid BredtChief Scientific Officer · sold 8,500 at avg $26.84228K2.1% of stake
- Dec 31, 2025No planDavid BredtChief Scientific Officer · sold 6,567 at $30.05197K1.6% of stake
- Dec 31, 2025No planKrishnaswamy YeleswaramChief Development Officer · sold 2,840 at $30.0585K0.9% of stake
- Dec 17, 202510b5-1 planAbraham CeesayChief Executive Officer · sold 10,916 at avg $29.64324K1.6% of stake
- Dec 15, 202510b5-1 planDavid BredtChief Scientific Officer · sold 8,500 at avg $30.02255K2.1% of stake
- Nov 26, 202510b5-1 planCheryl GaultChief Operating Officer · sold 5,000 at $30.10151K2.8% of stake
- Nov 17, 202510b5-1 planAbraham CeesayChief Executive Officer · sold 10,916 at avg $25.20275K1.6% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with RAPP
Held by ETFs
RAPP is in 32 US ETFs. The largest of them, with RAPP's weight in each:
Spot a number that looks wrong? Check it in RAPP's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing RAPP
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.